Curricular Unit:			Code:
New Therapeutic Systems			843NSTR
Year:	Level:	Course:	Credits:
5	Master	Pharmaceutical Sciences	5 ects
Learning Period:		Language of Instruction:	Total Hours:
Winter Semester		Portuguese/English	65
Learning Outcomes of the Curricular Unit:
According to the enormous development of new therapeutic systems in recent years, this Course Unit (CU) has the goal to provide students with essential knowledge relating to novel dosage forms intended for administration of drugs. At the end of the CU student must: - Know the limitations associated with the use of conventional dosage forms. - Recognize the need of develop strategies to improve the bioavailability of new drugs. - Distinguish the different types of forms and strategies of modified drug release. - Know various systems of encapsulation of active substances. - Identify and characterize different colloidal systems: liposomes; micelles; nanoemulsions; Polymeric, Lipid, Protein and Metal Nanoparticles; Drug nanocrystals; Dendrimers and Fullerenes. - Understand the advantages and limitations of new therapeutic systems for clinical application. - Acquire capacities of laboratorial preparation of these dosage forms.
Syllabus:
Units 1 and 2 teaching 1. Introduction to new therapeutic systems 2. Systems for modified drug release 2.1. Encapsulation systems for active substances 3. Types of nanosystems 3.1. Liposomes 3.2. Micelles 3.3. Micro and nanoemulsions 3.4. Nanoparticles: Polymeric, Lipid, Protein and Metallic 3.8. Drug nanocrystals 3.9. Dendrimers 3.10. Fullerenes 4. Methods of characterization of nanosystems 5. Other strategies for modified release: smart polymers, cyclodextrins 6. Modified release dosage forms Teaching Unit 3 1. Literature research regarding a new dosage form for the administration of drugs. 2. Oral presentation of research work. 3. Laboratorial preparation of lipid nanoparticles systems and modified release tablets
Demonstration of the Syllabus Coherence with the Curricular Unit's Objectives:
Students should acquire knowledge of the novel therapeutic systems and the importance of its development, taking into account the current clinical reality, with respect to new drug molecules. The need to develop new drug delivery systems, according to the limitations of conventional dosage forms will be explained. Students will also be encouraged to deepen their knowledge about the new pharmaceutical forms for administration of drugs, with particular emphasis on pharmaceutical forms, which are already in clinical practice or in clinical trials, through literature.
Teaching Methodologies (Including Evaluation):
The evaluation of the theoretical component comprises the execution of two written tests. The final classification will be calculated using the average of the results obtained in the two written tests (2 ECTS). The minimum passing classification is 9,5. For the student to be evaluated in the theoretical component of the UC, must attend at 50% of classes. The evaluation of the laboratory component comprises: a continuous evaluation of the autonomous execution of theoretical-practical and laboratory work (30%); execution of a written report (30%); oral presentation of a research work (40%). The minimum passing classification for the laboratory component of the Curricular Unit (CU) is 9.5 (2 ECTS). For the student to be evaluated for the CU, must attend at 80% of the laboratory classes. The approval of the CU is obtained by the average (higher than 10) of the theoretical (80%) and laboratory (20%) components.
Demonstration of the Coherence between the Teaching Methodologies and the Learning Outcomes:
The evaluation of the theoretical component comprises the execution of two written tests. The final classification will be calculated using the average of the results obtained in the two written tests (2 ECTS). The minimum passing classification is 9,5. For the student to be evaluated in the theoretical component of the UC, must attend at 50% of classes. The evaluation of the laboratory component comprises: a continuous evaluation of the autonomous execution of theoretical-practical and laboratory work (20%); execution of a writing test (40%); oral presentation of a research work (40%). The minimum passing classification for the laboratory component of the Curricular Unit (CU) is 9.5 (2 ECTS). For the student to be evaluated for the CU, must attend at 80% of the laboratory classes. The approval of the CU is obtained by the average (higher than 10) of the theoretical (80%) and laboratory (20%) components.
Reading:
1. Souto, E.B. and Lopes, C.M., Novas Formas Farmacêuticas para Administração de Fármacos, Fundação Fernando Pessoa, 2011 2. Farmacopeia Portuguesa 9, 2008 3. Silva, A.C., et al. (2012). Curr Med Chem, 19 (26): 4495 - 4510 4. Silva, A.C., et al. (2013). Curr Pharm Des, 19 (41):7185-95. 5. Silva, A.C., et al. (2015). Curr Drug Metabol, 16 (1): 3-16 6. Silva, A.C., et al. (2015). Curr Pharm Biotech 16 (4): 291-302 7. Silva, A.C., et al. (2015). Curr Pharm Biotech 16 (11): 940-954 8. Silva, A.C., et al. (2015). Curr Pharm Biotech, 16 (11): 955-965 9. Duncan, R. and Gaspar, R. (2011). Molecular Pharm, 8 (6): 2101–2141 10. Sonke Svenson (2014).WIR: Nanomed Nanobiotech 12. Matthias Wacker (2013). Int J Pharm, 457: 50-62 13. Weissig, V. et al. (2014), Int J Nanomed, 9: 4357–4373 14. Chen, H. et al. (2011). Drug Discov Today, 16: 354-360 15. http://www.fda.gov/ForConsumers/default.htm 16. https://www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html 17. www.malvern.com
Lecturer (* Responsible):
Ana Catarina da Silva (acsilva@ufp.edu.pt)